Eos’ Post

Eos reposted this

View organization page for Laverock Therapeutics, graphic

4,580 followers

At Laverock we are continuing to validate the unique features of our technology and now have a complete set of data in human cells demonstrating the ability to silence genes in a programmable, tunable, stable and highly specific manner. We have also demonstrated that the technology can be used to concomitantly silence more than one target gene, further expanding the range of its potential therapeutic applications. The attached data shows simultaneous silencing of two different targets using Laverock’s gene silencing RNAs. GFP-expressing human iPS cells were edited to express RNA of two designs - one targeting GFP the other targeting B2M. This leads to the silencing of both targets with highly correlated efficiencies (GEiGS/WT, GEiGS/GEiGS). The silencing is highly homogenous and the efficiency is also dependent on whether the edit is mono- (GEiGS/WT) or bi-allelic (GEiGS/GEiGS). This shows that Laverock’s approach, can enable the stable and homogenous silencing of multiple targets simultaneously. The silencing efficiency can be tuned through the design of the silencing RNAs and number of alleles edited. We look forward to presenting more detail and further scientific developments at conferences over the rest of the year. Do get in touch if you’d like to discuss our technology and follow us to keep up to date on our news advances. #cellandgenetherapy #genesilencing #advancedtherapies

  • No alternative text description for this image
Silvia Logan, MA in Classical Studies

I bake goodies for the homeless women in Cornerstone. at I do volunteer work at St. Matthew's Church.

2w

It is good that more progress is being done.

Like
Reply
Elizabeth Klein

Interested in UK based small and mid-sized Life Sciences businesses, and the wider Life Science investing ecosytem..

2w

Great progress.

Like
Reply
John Brown

Experienced Chairman /Non -Exec Director

2w

More progress!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics